Phase II Study of the Combination of Bendamustine and Dexamethasone in Patients with Relapsed AL Amyloidosis
Study For Previously Treated Patients Of Amyloidosis Using Bendamustine and Dexamethasone
Sponsor: Cephalon Inc.
Enrolling: Male and Female Patients
IRB Number: AAAJ7800
U.S. Govt. ID: NCT01222260
Contact: Ryan Shelton: 212-304-5480 /
Additional Study Information: The study is being done to see if the combination of bendamustine and dexamethasone will help people with amyloidosis that has returned after standard treatment. Bendamustine is currently approved by the Food and Drug Administration (FDA) for treatment of chronic lymphocytic leukemia (CLL) and is under clinical development in the United States for the treatment of non-Hodgkin lymphoma (NHL). Dexamethasone is a synthetic (man-made) steroid with powerful anti-inflammatory effects. It can also alter your body's immune response.
This study is closed
Suzanne Lentzsch, MD
Do You Qualify?
Do you have amyloidosis? Yes No
Have you received a stem cell transplant? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Ryan Shelton